首页 | 本学科首页   官方微博 | 高级检索  
检索        

川芎嗪对肿瘤介导的血液高凝的影响
引用本文:王生,赵杨,陶丽,王爱云,陈文星,郑仕中,陆茵.川芎嗪对肿瘤介导的血液高凝的影响[J].中国药理学通报,2012,28(5):709-715.
作者姓名:王生  赵杨  陶丽  王爱云  陈文星  郑仕中  陆茵
作者单位:1. 江苏省中药药效与安全性评价重点实验室,南京中医药大学药学院,江苏,南京,210046
2. 江苏省中药药效与安全性评价重点实验室,南京中医药大学药学院,江苏,南京,210046;江苏省中药药效与安全性评价重点实验室,南京中医药大学中药学一级学科,江苏,南京,210046
基金项目:国家自然科学基金资助项目,江苏省自然科学基金资助项目,江苏省国际合作项目,江苏省教育厅重大专项,江苏省六大人才高峰课题A类第五批项目资助,江苏省中医药局项目,江苏省中药药效与安全性评价重点实验室开放课题,江苏省普通高校研究生科研创新计划项目,江苏高校优势学科建设工程资助项目
摘    要:目的研究川芎嗪抗肿瘤转移作用与改善肿瘤介导的高凝状态两者之间的相关性。方法采用C57BL6小鼠的实验性转移模型,考察川芎嗪体内对肿瘤血行转移的影响,通过血液APTT、PT、TT、FIB检测考察肿瘤对凝血时间的影响及药物对其的改善作用,同时通过ELISA方法检测血浆t-PA、u-PA、PAI反映纤溶系统的活性变化,测定血浆中纤维蛋白肽A反映纤维蛋白的生成情况,检测血浆中FXⅢ来反映纤维蛋白的稳定程度。结果体内川芎嗪72 mg·kg-1能够抑制B16F10实验转移,明显减少肺转移结节数量。实验性转移模型组与正常组相比,凝血时间明显缩短,表现出血液高凝状态,给予川芎嗪8、24、72 mg·kg-1,不同时间均可以不同程度的延长APTT、PT、TT、FIB,并能抑制纤维蛋白的形成和稳定,进而改善肿瘤引起的血液高凝。结论肿瘤转移会引起血液的高凝,且随着转移时间的延长,血液高凝程度加剧。川芎嗪能够改善肿瘤介导的高凝状态,可能与其抗肿瘤转移作用相关。

关 键 词:血液高凝  川芎嗪  纤维蛋白原  实验性转移  肿瘤  纤溶系统

The effect of Ligustrazine on tumor-mediated hypercoagulability
WANG Sheng , ZHAO Yang , TAO Li , WANG Ai-yun , CHEN Wen-xing , ZHENG Shi-zhong , LU Yin.The effect of Ligustrazine on tumor-mediated hypercoagulability[J].Chinese Pharmacological Bulletin,2012,28(5):709-715.
Authors:WANG Sheng  ZHAO Yang  TAO Li  WANG Ai-yun  CHEN Wen-xing  ZHENG Shi-zhong  LU Yin
Institution:1,2(1.Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica,2.College of Pharmacy,Nanjing University of Chinese Medicine,National First-Class Key Discipline for Traditional Chinese Medicine of Nanjing University of Chinese Medicine,Nanjing 210046,China)
Abstract:Aim To study the association between antimetastasis and improvement of tumor-mediated hypercoagulability of Ligustrazine of the main component of traditional Chinese medicine Chuanxiong.Methods The experimental metastasis model was used to study the overall efficacy of anti-metastasis of Ligustrazine.The APTT,PT,TT,FIB were tested to evaluate the effect of tumor on coagulation system and improvement of Ligustrazine.The change in the activity of fibrinolytic system was detected plasma level of t-PA,u-PA,PAI by Elisa kit.Fibrin formation was assessed by detecting plasma fibrinopeptide A(FPA) by FPA Elisa kit.The FXIII Elisa Kit was used to detect the stability of fibrin.Results Ligustrazine 72 mg·kg-1 inhibited B16F10 experimental metastasis in vivo,a significant reduction in the number of lung nodules.Clotting time of experimental metastasis model group was significantly reduced compared with normal group,showing hypercoagulability.The coagulation time of APTT,PT,TT,FIB was extended to some different extent after treatment by Ligustrazine 8 mg·kg-1,24 mg·kg-1,72 mg·kg-1 at 7,14,21th day.Besides,Ligustrazine could inhibit fibrin formation and stability,thereby improving tumor-induced hypercoagulability.Conclusions Tumor metastasis can cause blood coagulation and activate blood system,and with the transfer time extend,the hypercoagulability is more serious.Ligustrazine can inhibit tumor metastasis which may be related to the improvement of the tumor-mediated hypercoagulable state.
Keywords:blood coagulation  Ligustrazine  fibrinogen  experimental metastasis  tumor  fibrinolytic system
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号